148 related articles for article (PubMed ID: 17116296)
1. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells.
Murphey C; Murthy AK; Meier PA; Neal Guentzel M; Zhong G; Arulanandam BP
Cell Immunol; 2006 Aug; 242(2):110-7. PubMed ID: 17116296
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.
Li W; Murthy AK; Guentzel MN; Seshu J; Forsthuber TG; Zhong G; Arulanandam BP
J Immunol; 2008 Mar; 180(5):3375-82. PubMed ID: 18292563
[TBL] [Abstract][Full Text] [Related]
3. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele.
Murthy AK; Cong Y; Murphey C; Guentzel MN; Forsthuber TG; Zhong G; Arulanandam BP
Infect Immun; 2006 Dec; 74(12):6722-9. PubMed ID: 17015458
[TBL] [Abstract][Full Text] [Related]
4. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.
Murthy AK; Chambers JP; Meier PA; Zhong G; Arulanandam BP
Infect Immun; 2007 Feb; 75(2):666-76. PubMed ID: 17118987
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.
Cong Y; Jupelli M; Guentzel MN; Zhong G; Murthy AK; Arulanandam BP
Vaccine; 2007 May; 25(19):3773-80. PubMed ID: 17349723
[TBL] [Abstract][Full Text] [Related]
6. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.
Li W; Murthy AK; Lanka GK; Chetty SL; Yu JJ; Chambers JP; Zhong G; Forsthuber TG; Guentzel MN; Arulanandam BP
Vaccine; 2013 Nov; 31(48):5722-8. PubMed ID: 24096029
[TBL] [Abstract][Full Text] [Related]
7. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model.
Hansen J; Jensen KT; Follmann F; Agger EM; Theisen M; Andersen P
J Infect Dis; 2008 Sep; 198(5):758-67. PubMed ID: 18652549
[TBL] [Abstract][Full Text] [Related]
8. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach.
Li W; Guentzel MN; Seshu J; Zhong G; Murthy AK; Arulanandam BP
Clin Vaccine Immunol; 2007 Dec; 14(12):1537-44. PubMed ID: 17942608
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with recombinant chlamydial protease-like activity factor attenuates atherosclerotic pathology following Chlamydia pneumoniae infection in mice.
Li W; Gudipaty P; Li C; Henderson KK; Ramsey KH; Murthy AK
Immunol Cell Biol; 2019 Jan; 97(1):85-91. PubMed ID: 30051926
[TBL] [Abstract][Full Text] [Related]
10. The role of an enzymatically inactive CPAF mutant vaccination in Chlamydia muridarum genital tract infection.
Chen H; Peng B; Yang C; Xie L; Zhong S; Sun Z; Li Z; Wang C; Liu X; Tang X; Zhong G; Lu C
Microb Pathog; 2021 Nov; 160():105137. PubMed ID: 34390765
[TBL] [Abstract][Full Text] [Related]
11. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge.
Chaganty BK; Murthy AK; Evani SJ; Li W; Guentzel MN; Chambers JP; Zhong G; Arulanandam BP
Vaccine; 2010 Mar; 28(11):2323-9. PubMed ID: 20056182
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge.
Murthy AK; Li W; Guentzel MN; Zhong G; Arulanandam BP
Vaccine; 2011 Mar; 29(14):2519-22. PubMed ID: 21300093
[TBL] [Abstract][Full Text] [Related]
13. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
He Q; Martinez-Sobrido L; Eko FO; Palese P; Garcia-Sastre A; Lyn D; Okenu D; Bandea C; Ananaba GA; Black CM; Igietseme JU
Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection.
Powell HJ; Cong Y; Yu JJ; Guentzel MN; Berton MT; Klose KE; Murthy AK; Arulanandam BP
Immunol Cell Biol; 2008; 86(6):515-22. PubMed ID: 18427567
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.
Li W; Murthy AK; Guentzel MN; Chambers JP; Forsthuber TG; Seshu J; Zhong G; Arulanandam BP
Infect Immun; 2010 Sep; 78(9):3942-9. PubMed ID: 20605976
[TBL] [Abstract][Full Text] [Related]
16. Protective anti-chlamydial vaccine regimen-induced CD4+ T cell response mediates early inhibition of pathogenic CD8+ T cell response following genital challenge.
Murthy AK; Wright-McAfee E; Warda K; Moy LN; Bui N; Musunuri T; Manam S; Chako CZ; Ramsey KH; Li W
Pathog Dis; 2024 Feb; 82():. PubMed ID: 38684476
[TBL] [Abstract][Full Text] [Related]
17. Route of Vaccine Administration Influences the Impact of Fms-Like Tyrosine Kinase 3 Ligand (Flt3L) on Chlamydial-Specific Protective Immune Responses.
Pais R; Omosun Y; Igietseme JU; Fujihashi K; Eko FO
Front Immunol; 2019; 10():1577. PubMed ID: 31333682
[TBL] [Abstract][Full Text] [Related]
18. Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.
Marks E; Verolin M; Stensson A; Lycke N
Infect Immun; 2007 Sep; 75(9):4638-47. PubMed ID: 17635872
[TBL] [Abstract][Full Text] [Related]
19. Antigen-Specific CD4
Lin H; He C; Koprivsek JJ; Chen J; Zhou Z; Arulanandam B; Xu Z; Tang L; Zhong G
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30962403
[TBL] [Abstract][Full Text] [Related]
20. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H; Jiang X; Shen C; Karunakaran KP; Jiang J; Rosin NL; Brunham RC
Infect Immun; 2010 May; 78(5):2272-82. PubMed ID: 20231405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
